Actelion Pharmaceuticals v. Mylan Pharmaceuticals (Fed. Cir., May 13, 2026) 2024-1641
In this episode, the United States Court of Appeals for the Federal Circuit affirmed that Mylan Pharmaceuticals Inc.did not infringe upon patents held by Actelion Pharmaceuticals Ltd. regarding the hypertension drug Veletri®. The legal dispute centered on the requirement that the drug be manufactured from a "bulk solution" with a pH of 13 or higher, a threshold Actelion claimed was met by Mylan’s refrigerated process. However, the court determined that the term "pH" refers to measurements taken at a standard temperature of 25°C, a condition Mylan's product did not satisfy. Furthermore, the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.